Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.,
Company profile
Ticker
ARTH
Exchange
Website
CEO
Terrence W. Norchi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ALMAH,INC
SEC CIK
Corporate docs
IRS number
460524102
ARTH stock data
Latest filings (excl ownership)
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Mar 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1 Mar 24
10-Q
2024 Q1
Quarterly report
20 Feb 24
NT 10-Q
Notice of late quarterly filing
15 Feb 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7 Feb 24
8-K
Changes in Registrant's Certifying Accountant
12 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
Latest ownership filings
SC 13G/A
Parker Michael Andrew
22 Jan 24
4
MICHAEL S ABRAMS
8 Sep 23
4
Terrence W Norchi
8 Sep 23
4
Laurence Hicks
8 Sep 23
SC 13G
Stahl Andrew
9 Aug 23
SC 13G
wilson brandt
25 Jul 23
SC 13G
BIGGER CAPITAL FUND L P
14 Jul 23
SC 13G
Oasis Capital, LLC
12 Jul 23
SC 13G/A
Parker Michael Andrew
27 Jan 23
SC 13G/A
Parker Michael Andrew
25 Jan 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Aug 23 | Laurence Hicks | Common Stock | Buy | Acquire P | Yes | No | 0.275 | 10,292 | 2.83 k | 10,292 |
31 Aug 23 | Laurence Hicks | Warrants Common Stock | Grant | Acquire A | Yes | No | 1 | 20,584 | 20.58 k | 20,584 |
31 Aug 23 | Michael S Abrams | Common Stock | Buy | Acquire P | No | No | 0.275 | 10,292 | 2.83 k | 10,292 |
31 Aug 23 | Michael S Abrams | Warrants Common Stock | Grant | Acquire A | No | No | 1 | 20,584 | 20.58 k | 20,584 |
31 Aug 23 | Norchi Terrence W | Common Stock | Buy | Acquire P | No | No | 0.275 | 6,862 | 1.89 k | 6,862 |
31 Aug 23 | Norchi Terrence W | Warrants Common Stock | Grant | Acquire A | No | No | 1 | 13,724 | 13.72 k | 13,724 |
10 Nov 22 | Michael S Abrams | Stock Option Common Stock | Grant | Acquire A | No | No | 0.0401 | 900,000 | 36.09 k | 900,000 |
10 Nov 22 | Norchi Terrence W | Stock Option Common Stock | Grant | Acquire A | No | No | 0.0401 | 1,250,000 | 50.12 k | 1,250,000 |